https://www.fresenius.com en-us Mon, 15 Apr 2024 23:48:50 +0200 Mon, 15 Apr 2024 23:48:50 +0200 Mon, 15 Apr 2024 23:48:50 +0200 here. With #FutureFresenius, Fresenius successfully set the course last year to become a leading therapy-focused company. In line with the strategy, Fresenius has simplified its structure, is sharpening its focus by concentrating on its operating companies Fresenius Kabi and Fresenius Helios and is continuously enhancing its performance.  About Tyenne®, a Tocilizumab Biosimilar Tyenne® (tocilizumab-aazg), a biosimilar to Actemra® (tocilizumab), is a prescription medicine called an Interleukin-6 (IL-6) receptor antagonist. It was developed by Fresenius Kabi using advanced analytical and manufacturing technologies for use in the treatment of several autoimmune diseases, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial, invasive fungal, viral, and other opportunistic infections have occurred in patients receiving the product. Tyenne® is contraindicated in patients with known hypersensitivity to tocilizumab products. For more information about Tyenne®, please see the full prescribing information for the U.S. here. Tyenne® demonstrates Fresenius Kabi’s commitment to providing access to affordable and cost-effective biosimilars to more patients living with autoimmune diseases around the world while enabling savings for health care systems. KabiCare, Fresenius Kabi’s comprehensive patient support program, will be available to patients and health care providers in the U.S. from launch.  About Fresenius Kabi  Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used for the therapy and care of critically and chronically ill patients.  Its product portfolio comprises a range of highly complex biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs. Within biopharmaceuticals, Fresenius Kabi offers, among others, biosimilar drugs with a focus on autoimmune diseases and oncology. The company’s clinical nutrition offering includes a wide selection of enteral and parenteral nutrition products. In the segment of medical technologies, its offering includes vital disposables, infusions pumps, apheresis machines, cell therapy devices, and more. Fresenius Kabi puts essential medicines and technologies in the hands of people who help patients and finds the best answers to the challenges they face.  Following its strategy “Vision 2026”, which is a key part of the #FutureFresenius program of the Fresenius healthcare group, the company is furthermore committed to increase efficiencies in the therapy and care of patients and improve access to high-quality healthcare around the globe. Fresenius Kabi aspires to be leading globally in its product segments – all for the benefit of patients, its customers, and its stakeholders. *Tyenne® is a registered trademark of Fresenius Kabi Deutschland GmbH.  **Actemra® is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group.  ***Idacio® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries ****Stimufend® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries  ]]> Thu, 04 Apr 2024 20:30:13 +0200 Thu, 04 Apr 2024 20:00:00 +0200 Mon, 18 Mar 2024 17:00:00 +0100 Fri, 08 Mar 2024 16:00:00 +0100 Thu, 07 Mar 2024 17:00:00 +0100 Wed, 28 Feb 2024 21:00:00 +0100 Tue, 27 Feb 2024 14:14:54 +0100 Wed, 21 Feb 2024 14:00:00 +0100 Tue, 20 Feb 2024 17:15:52 +0100 Mon, 05 Feb 2024 19:00:00 +0100 Wed, 31 Jan 2024 18:29:33 +0100 Mon, 29 Jan 2024 22:00:00 +0100 Fri, 12 Jan 2024 17:28:39 +0100 Wed, 20 Dec 2023 15:00:00 +0100 Fri, 15 Dec 2023 15:29:38 +0100 Thu, 14 Dec 2023 21:00:00 +0100 Wed, 06 Dec 2023 00:07:54 +0100 Thu, 30 Nov 2023 16:15:36 +0100 Wed, 22 Nov 2023 04:12:49 +0100